Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | CASP3 | P42574 | 3/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | CASP1 | P29466 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28215462 | 1.00 | MDM4 (0.48) | MDM4TP53CASP3EPHX2KMT2A | |
| SCHEMBL3421848 | 1.00 | MDM4 (0.48) | MDM4TP53CASP3EPHX2KMT2A | |
| SCHEMBL31000608 | 1.00 | MDM4 (0.48) | MDM4TP53CASP3EPHX2KMT2A | |
| SCHEMBL13908450 | 0.90 | KMT2A (0.52) | MDM4TP53CASP3EPHX2KMT2A | |
| SCHEMBL21764273 | 0.90 | MDM4 (0.47) | MDM4TP53CASP3EPHX2KMT2A | |
| SCHEMBL29532800 | 0.90 | MDM4 (0.47) | MDM4TP53CASP3EPHX2KMT2A | |
| SCHEMBL26008669 | 0.90 | KMT2A (0.52) | MDM4TP53CASP3EPHX2KMT2A | |
| SCHEMBL31307731 | 0.90 | KMT2A (0.52) | MDM4TP53CASP3EPHX2KMT2A | |
| SCHEMBL31000515 | 0.90 | MDM4 (0.47) | MDM4TP53CASP3EPHX2KMT2A | |
| SCHEMBL21785029 | 0.89 | HDAC1 (0.46) | MDM4TP53CASP3EPHX2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240140991-A1 | ANTIBIOTIC NATURAL PRODUCT ANALOGUES | UNIV BELFAST (GB) | 2024-05-02 | — | — | US | disclosed |
| EP-4284816-A1 | ANTIBIOTIC NATURAL PRODUCT ANALOGUES | The Queen's University of Belfast (GB) | 2023-12-06 | — | — | EP | disclosed |
| WO-2022162332-A1 | ANTIBIOTIC NATURAL PRODUCT ANALOGUES | THE QUEEN'S UNIVERSITY OF BELFAST (GB) | 2022-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240140991-A1 | ANTIBIOTIC NATURAL PRODUCT ANALOGUES | NRDC, RPS14, SCN11A | MDM4 4676/4885TP53 4057/4885CASP3 2372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.